Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Sell
45
NVS Quote, Financials, Valuation and Earnings
Last price:
$112.23
Seasonality move
:
5.08%
Day range:
$110.61 - $112.42
52-week range:
$92.35 - $120.92
Dividend yield:
3.45%
P/E ratio:
19.09x
P/S ratio:
4.41x
P/B ratio:
5.03x
Volume:
4.9M
Avg. volume:
2.3M
1-year change:
15.37%
Market cap:
$221.6B
Revenue:
$51.7B
EPS (TTM):
$5.88
Analysts' Opinion
-
Consensus RatingNovartis AG has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 9 Hold ratings, and 2 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $109.37, Novartis AG has an estimated downside of -2.54% from its current price of $112.22.
-
Price Target UpsideAccording to analysts, the highest upside price target is $125.00 representing 11.39% upside increase from its current price of $112.22.
Fair Value
-
According to the consensus of 11 analysts, Novartis AG has -2.54% downside to fair value with a price target of $109.37 per share.
NVS vs. S&P 500
-
Over the past 5 trading days, Novartis AG has underperformed the S&P 500 by -0.7% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Novartis AG does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novartis AG has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Novartis AG reported revenues of $13.6B.
Earnings Growth
-
Novartis AG earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Novartis AG reported earnings per share of $1.41.
Enterprise value:
237.8B
EV / Invested capital:
3.23x
Price / LTM sales:
4.41x
EV / EBIT:
16.24x
EV / Revenue:
4.60x
PEG ratio (5yr expected):
0.09x
EV / Free cash flow:
17.23x
Price / Operating cash flow:
16.54x
Enterprise value / EBITDA:
11.48x
Gross Profit (TTM):
$38.9B
Return On Assets:
12%
Net Income Margin (TTM):
23.09%
Return On Equity:
27.64%
Return On Invested Capital:
16.91%
Operating Margin:
26.04%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $47.6B | $46.7B | $51.7B | $11.8B | $13.6B | |
| Gross Profit | $34.1B | $34.2B | $38.9B | $8.8B | $10.2B | |
| Operating Income | $8.7B | $9.8B | $14.5B | $2.6B | $3.5B | |
| EBITDA | $15.6B | $18.3B | $20.7B | $4.2B | $5.2B | |
| Diluted EPS | $3.16 | $7.10 | $5.88 | $4.06 | $1.41 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $29.7B | $45.7B | $36.9B | $30.5B | $29.7B | |
| Total Assets | $127.8B | $131.8B | $117.5B | $99.9B | $102.2B | |
| Current Liabilities | $33.1B | $30.2B | $28.7B | $26.4B | $28.7B | |
| Total Liabilities | $71.1B | $64B | $58B | $53.2B | $58.1B | |
| Total Equity | $56.7B | $67.8B | $59.4B | $46.8B | $44.1B | |
| Total Debt | $35.9B | $29.1B | $26.1B | $24.5B | $29.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $14.2B | $14.5B | $17.6B | $2.5B | $4.2B | |
| Cash From Investing | $1.5B | $5.6B | -$7.5B | -$1.8B | -$3B | |
| Cash From Financing | -$20.6B | -$14.3B | -$11.7B | -$607M | -$3B | |
| Free Cash Flow | $12B | $11.7B | $13.8B | $1.8B | $3.1B | |
NVS
Sector
Market Cap
$221.6B
$37.4M
Price % of 52-Week High
92.81%
45.61%
Dividend Yield
3.45%
0%
Shareholder Yield
7.56%
-0.75%
1-Year Price Total Return
15.37%
-38.36%
Beta (5-Year)
0.540
0.774
Dividend yield:
3.45%
Annualized payout:
$3.74
Payout ratio:
63.85%
Growth streak:
5 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$111.34
200-day SMA
Buy
Level
$108.14
Bollinger Bands (100)
Buy
Level
99.49 - 110.33
Chaikin Money Flow
Buy
Level
319.1M
20-day SMA
Buy
Level
$109.58
Relative Strength Index (RSI14)
Buy
Level
58.86
ADX Line
Buy
Level
40.84
Williams %R
Neutral
Level
-49.8936
50-day SMA
Buy
Level
$104.83
MACD (12, 26)
Buy
Level
1.62
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
219.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
Buy
CA Score
(Annual)
Level (0.1527)
Buy
Beneish M-Score
(Annual)
Level (-2.6826)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-1.5197)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Stock Forecast FAQ
In the current month, NVS has received 0 Buy ratings 9 Hold ratings, and 2 Sell ratings. The NVS average analyst price target in the past 3 months is $109.37.
-
Where Will Novartis AG Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novartis AG share price will drop to $109.37 per share over the next 12 months.
-
What Do Analysts Say About Novartis AG?
Analysts are divided on their view about Novartis AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that Novartis AG is a Buy and believe this share price will rise from its current level to $125.00.
-
What Is Novartis AG's Price Target?
The price target for Novartis AG over the next 1-year time period is forecast to be $109.37 according to 11 Wall Street analysts, 0 of them rate the stock a Buy, 2 rate the stock a Sell, and 9 analysts rate the stock a Hold.
-
Is NVS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novartis AG is a Hold. 9 of 11 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NVS?
You can purchase shares of Novartis AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novartis AG shares.
-
What Is The Novartis AG Share Price Today?
Novartis AG was last trading at $112.23 per share. This represents the most recent stock quote for Novartis AG. Yesterday, Novartis AG closed at $112.22 per share.
-
How To Buy Novartis AG Stock Online?
In order to purchase Novartis AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 18
Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.
Buy
63
EXOD alert for Mar 18
Exodus Movement [EXOD] is down 3.96% over the past day.
Sell
45
MNPR alert for Mar 18
Monopar Therapeutics [MNPR] is up 0.93% over the past day.
